» Articles » PMID: 34846064

Variation in Dexamethasone Dosing and Use Outcomes for Inpatient Croup

Overview
Journal Hosp Pediatr
Specialty Pediatrics
Date 2021 Nov 30
PMID 34846064
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Evaluate the association between dexamethasone dosing and outcomes for children hospitalized with croup.

Methods: This study was nested within a multisite prospective cohort study of children aged 6 months to 6 years admitted to 1 of 5 US children's hospitals between July 2014 and June /2016. Multivariable linear and logistic mixed-effects regression models were used to examine the association between the number of dexamethasone doses (1 vs >1) and outcomes (length of stay [LOS], cost, and 30-day same-cause reuse). All multivariable analyses included a site-specific random effect to account for clustering within hospital and were adjusted for age, sex, race and ethnicity, presenting severity, medical complexity, insurance, caregiver education, and hospital. In cost analyses, we controlled for LOS.

Results: Among 234 children hospitalized with croup, patient characteristics did not differ by number of doses. The proportion receiving >1 dose varied by hospital (range 27.9%-57.1%). In adjusted analyses, >1 dose was not associated with same-cause reuse (odds ratio 0.87 [95% confidence interval (CI): 0.26 to 2.95]) but was associated with 45% longer LOS (relative risk = 1.45 [95% CI: 1.30 to 1.62]). When we controlled for LOS, >1 dose was not associated with differential cost ($-31.2 [95% CI $-424.4 to $362.0]). Eighty-two (35%) children received dexamethasone before presentation.

Conclusions: We found significant interhospital variation in dexamethasone dosing and LOS. When we controlled for severity on presentation, >1 dexamethasone dose was associated with longer LOS but not reuse. Although incomplete adjustment for severity is one possible explanation, some providers may routinely keep children hospitalized to administer multiple dexamethasone doses.

Citing Articles

Astragalus Extract Mixture HT042 Alleviates Dexamethasone-Induced Bone Growth Retardation in Rat Metatarsal Bones.

Baek C, Lee J, Lee D, Kim H Nutrients. 2024; 16(14).

PMID: 39064775 PMC: 11279921. DOI: 10.3390/nu16142333.


An Overview of the Effectiveness of Corticoids in Croup: A Systematic Literature Review.

Garzon Mora N, Jaramillo A, Briones Andriuoli R, Torres S, Revilla J, Moncada D Cureus. 2023; 15(10):e46317.

PMID: 37916233 PMC: 10616678. DOI: 10.7759/cureus.46317.


Glucocorticoids for croup in children.

Aregbesola A, Tam C, Kothari A, Le M, Ragheb M, Klassen T Cochrane Database Syst Rev. 2023; 1:CD001955.

PMID: 36626194 PMC: 9831289. DOI: 10.1002/14651858.CD001955.pub5.

References
1.
Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson D . Glucocorticoids for croup in children. Cochrane Database Syst Rev. 2018; 8:CD001955. PMC: 6513469. DOI: 10.1002/14651858.CD001955.pub4. View

2.
Leyenaar J, Ralston S, Shieh M, Pekow P, Mangione-Smith R, Lindenauer P . Epidemiology of pediatric hospitalizations at general hospitals and freestanding children's hospitals in the United States. J Hosp Med. 2016; 11(11):743-749. PMC: 5467435. DOI: 10.1002/jhm.2624. View

3.
Petrocheilou A, Tanou K, Kalampouka E, Malakasioti G, Giannios C, Kaditis A . Viral croup: diagnosis and a treatment algorithm. Pediatr Pulmonol. 2014; 49(5):421-9. DOI: 10.1002/ppul.22993. View

4.
Mangione-Smith R, Roth C, Britto M, Chen A, McGalliard J, Boat T . Development and Testing of the ediatric espiratory llness asurement ystem (PRIMES) Quality Indicators. Hosp Pediatr. 2017; 7(3):125-133. DOI: 10.1542/hpeds.2016-0182. View

5.
Tyler A, Anderson L, Moss A, Graham J, Dempsey A, Carpenter T . Predictors of Symptom Rebound in Critically Ill Patients With Croup. Hosp Pediatr. 2019; 9(6):447-454. DOI: 10.1542/hpeds.2018-0195. View